← All trials
NCT07273799
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2025
- Primary completion
- May 1, 2026
- Completion date
- Jun 1, 2026
- First posted
- Dec 10, 2025
- Last posted
- Dec 10, 2025
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sheikh Zayed Medical CollegeLead sponsor
- Sheikh Zayed Medical CollegeSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.